Skip to main content

Featured

Lawyers Demand Justice After Quebec Teen’s Death

Lawyers representing the family of Nooran Rezayi , a 15-year-old boy fatally shot by police in Longueuil, Quebec, are calling for accountability after allegations of interference in the investigation. Rezayi was killed on September 21, 2025 , in a suburban neighborhood south of Montreal. Quebec’s police watchdog (BEI) has accused local officers of questioning witnesses and attempting to obtain video footage , actions that could compromise the independence of the probe. Lawyers for Rezayi’s family insist such interference cannot go unpunished. The family has filed a $2.2 million lawsuit against the Longueuil police and the city, claiming “unreasonable and disproportionate force” was used against the unarmed teen. His mother, Fahima Rezayi, has urged authorities to ensure accountability, stressing that “this must never happen again.” The case has sparked outrage and renewed calls for reform in Quebec’s policing system. Critics argue that protecting the watchdog’s independence is ess...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment